Clinical Trial Update: Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating enzalutamide with paclitaxel vs placebo with paclitaxel in advanced triple-negative breast cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 3 | Status: WITHDRAWN